CytomX Therapeutics Projects Varseta-M Registrational Study for First Half of 2027
CytomX Therapeutics (CTMX) provided an update on its clinical development progress during its Q3 2026 earnings call. The company announced that it expects to initiate its first potential registrational study for its lead program, Varseta-M, in the first half of 2027. In addition to clinical timelines, management provided guidance on the company's financial position, projecting a cash runway extending into the second half of 2028. This update aims to provide clarity on both the developmental milestones and the capital sufficiency required to reach upcoming clinical inflection points.
Tickers: $CTMX